Effect of inhibition of interleukin-12/23 by ustekinumab on the expression of leptin and leptin receptor in human THP-1 macrophages

Clinical and Experimental Dermatology

Volumn 41, Issue 3, 2016, Pages 308-311

  Voloshyna, I ^a   Mounessa, J ^a   Carsons, S E ^a   Reiss, A B ^a  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; INTERLEUKIN 12; INTERLEUKIN 23; LEPTIN; LEPTIN RECEPTOR; USTEKINUMAB; BIOLOGICAL MARKER; DERMATOLOGICAL AGENT; INTERLEUKIN DERIVATIVE;

ARTICLE; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOMODULATION; MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM;

ADALIMUMAB; BIOMARKERS; BLOTTING, WESTERN; DERMATOLOGIC AGENTS; HUMANS; INTERLEUKIN-12; INTERLEUKIN-23; INTERLEUKINS; LEPTIN; MACROPHAGES; PSORIASIS; RECEPTORS, LEPTIN; USTEKINUMAB;

EID: 84931840791     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/ced.12699     Document Type: Article

References (10)

1. Onumah N, Kircik L,. Psoriasis and its comorbidities. J Drugs Dermatol 2012; 11 (Suppl): s5-10.
2. Yin X, Cheng H, Zhang R, et al,. Combined effect of five single nucleotide polymorphisms related to IL23/Th17 pathway in the risk of psoriasis. Immunogenetics 2014; 66: 215-18.
3. Wilson NJ, Boniface K, Chan JR, et al,. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8: 950-7.
4. Eijnden SV, Goriely S, DeWit D, et al,. IL-23 up-regulates IL-10 and induces IL-17 synthesis by polyclonally activated naive T cells in human. Eur J Immunol 2005; 35: 469-75.
5. Eder L, Jayakar J, Pollock R, et al,. Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity. Ann Rheum Dis 2013; 72: 1956-61.
6. Dalamaga M, Papadavid E,. Adipocytokines and psoriasis: insights into mechanisms linking obesity and inflammation to psoriasis. World J Dermatol 2013; 2: 27-31.
7. Engvall IL, Tengstrand B, Brismar K, et al,. Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months. Arthritis Res Ther 2010; 12: 1-11.
8. Lebwohl M, Yeilding N, Szapary P, et al,. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J Am Acad Dermatol 2010; 63: 571-9.
9. Gisondi P, Conti A, Galdo G, et al,. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. Br J Dermatol 2013; 168: 1124-7.
10. Krieckaert CL, Nair SC, Nurmohamed MT, et al,. Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects. Ann Rheum Dis 2015; 74: 361-8.